Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE BTX opened at $2.15 on Friday. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The business has a 50 day simple moving average of $2.18 and a two-hundred day simple moving average of $1.81. The stock has a market capitalization of $126.48 million, a PE ratio of -0.95 and a beta of 4.61.

Hedge Funds Weigh In On Brooklyn ImmunoTherapeutics

An institutional investor recently raised its position in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC lifted its stake in Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,459,626 shares of the company’s stock after purchasing an additional 243,826 shares during the quarter. Renaissance Technologies LLC owned about 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.00% of the company’s stock.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.